Quick Comparison
| Noopept | PQQ | |
|---|---|---|
| Half-Life | 30-60 minutes (active metabolite cycloprolylglycine persists longer) | 3-5 hours (plasma), but effects on mitochondrial biogenesis persist |
| Typical Dosage | Standard: 10-30 mg sublingually or orally, 2-3 times daily. Sublingual administration provides faster onset. Do not exceed 30 mg per dose. | Standard: 10-20 mg daily. Often combined with CoQ10 (100-300 mg) for synergistic mitochondrial support. Higher doses (40 mg) are used in some research settings. |
| Administration | Oral or sublingual (sublingual preferred for faster onset and higher bioavailability). Available as powder, capsules, or sublingual tablets. | Oral (capsules, softgels). Best absorbed on an empty stomach. BioPQQ is the most studied branded form. |
| Research Papers | 10 papers | 10 papers |
| Categories |
Mechanism of Action
Noopept
Noopept modulates AMPA and NMDA receptors similarly to racetams through positive allosteric modulation. Its key distinguishing feature is upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) via activation of TrkB and TrkA receptor signaling cascades — these neurotrophins are essential for neuronal growth, survival, dendritic arborization, and synaptic plasticity. Noopept inhibits glutamate-induced excitotoxicity by reducing calcium influx through NMDA receptors and modulating the NR2B subunit. It activates the PI3K/Akt and MAPK/ERK pathways downstream of neurotrophin receptors. The active metabolite cycloprolylglycine (a cyclic dipeptide) has endogenous nootropic activity, potentially acting as a trace amine-associated receptor ligand. Neuroprotection is further mediated through antioxidant effects and mitochondrial stabilization.
PQQ
PQQ activates PGC-1alpha (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master transcriptional regulator of mitochondrial biogenesis. PGC-1alpha coactivates NRF-1 and NRF-2, which drive expression of mitochondrial transcription factor A (TFAM) and nuclear-encoded mitochondrial genes—the process of creating new mitochondria in existing cells. This is unique among commercially available supplements. PQQ also provides antioxidant protection through extremely efficient redox cycling at the N5 position; it can undergo thousands of oxidation-reduction cycles before being exhausted, estimated at 5,000x the efficiency of vitamin C. PQQ activates the CREB (cAMP response element-binding protein) signaling pathway and may enhance NGF signaling, supporting BDNF expression, synaptic plasticity, and neuronal survival.
Risks & Safety
Noopept
Common
Headache (especially without choline supplementation), irritability at higher doses, brain fog in some users.
Serious
No serious adverse effects documented.
Rare
Emotional blunting at high doses, insomnia, allergic reactions.
PQQ
Common
Very few — PQQ has an excellent safety profile at standard doses. Mild headache, fatigue initially.
Serious
No serious adverse effects documented.
Rare
Insomnia, irritability.
Full Profiles
Noopept →
A synthetic peptide-derived nootropic often grouped with racetams due to similar effects, though it is technically a dipeptide analog of piracetam. Roughly 1000x more potent by weight than piracetam, requiring only 10-30 mg per dose. It provides both immediate cognitive enhancement and long-term neuroprotective benefits through BDNF and NGF upregulation.
PQQ →
Pyrroloquinoline quinone is a redox cofactor that is the only known compound that can stimulate the growth of new mitochondria (mitochondrial biogenesis) in existing cells. Since mitochondrial density and function decline with age, PQQ addresses a root cause of age-related cognitive decline. It also provides potent antioxidant protection — estimated to be 5,000x more efficient at redox cycling than vitamin C.